FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280824> ?p ?o ?g. }

• W4379280824 endingPage "e20651" @default.
• W4379280824 startingPage "e20651" @default.
• W4379280824 abstract "e20651 Background: Thymic epithelial tumors (TETs) are rare malignancies associated with humoral and cell-mediated immunity dysregulations. Anti-syndrome coronavirus type 2 (SARS-CoV-2) vaccine is effective at preventing COVID-19 morbidity and mortality. We have previously shown an impaired seroconversion after 1 st and 2 nd anti-SARS-CoV-2 vaccine doses in TETs patients. The aim of this study was to evaluate the seroconversion rate after the third vaccine dose (booster) in TET patients who remained serologically negative after full vaccination. Methods: Starting from November 2021 to March 2022, consecutive TET patients found to be serologically negative after two SARS-Cov-2 mRNA vaccine (BNT162b2 by Pfizer-BioNTech) doses were enrolled. SARS-CoV-2 spike-binding IgG antibody serological levels were centrally analyzed by chemiluminescent immunoassay (CLIA) at two different time-points: T0 and T1 (before and one month after booster, respectively). Cut-off for Ab titers positivity was > 25 AU/mL. Results: Among the 23 enrolled patients, 10 (43.5%) were female and 13 (56.5%) males; 6 (26%) pts had thymic carcinoma and 17 (74%) had thymoma. Autoimmune disorders were detected in 20 patients (86.9%), of whom 3 (15%) suffered from Myasthenia Gravis, 8 (40%) from Good’s Syndrome, 7 (35%) from both diseases, and 2 (10%) from other autoimmune disorders. By the time of booster administration 2 pts were lost to follow up, 2 pts died, 5 pts suffered from SARS-CoV-2 infection and seroconverted. Of the remaining 14 pts, only 7 (50%) achieved seroconversion. Among these patients, 2 had active cancer disease, whereas the remaining were disease-free. On the other hand, among the 7 patients who did not achieve seroconversion after booster, 6 had active cancer disease. Moreover, 6 of these patients suffered from Good’s Syndrome. Conclusions: Our results suggest that the anti-SARS-CoV-2 third dose could contribute to improved seroconversion of TET patients who did respond to the first two doses. It remains to be investigated why half of the patients are still not achieving seroconversion after the booster and whether this is determined by the presence of active disease or by alterations in humoral and/or cell-mediated immune response. These data may have important clinical implications because they could help to better identify fragile patients who could benefit from improved vaccine protocols or from alternative prophylaxis strategies, such as the use of monoclonal antibodies." @default.
• W4379280824 created "2023-06-05" @default.
• W4379280824 creator A5009712410 @default.
• W4379280824 creator A5010994601 @default.
• W4379280824 creator A5015496746 @default.
• W4379280824 creator A5021770361 @default.
• W4379280824 creator A5023671070 @default.
• W4379280824 creator A5024350156 @default.
• W4379280824 creator A5034331446 @default.
• W4379280824 creator A5042430456 @default.
• W4379280824 creator A5046176373 @default.
• W4379280824 creator A5050025219 @default.
• W4379280824 creator A5051876165 @default.
• W4379280824 creator A5052916641 @default.
• W4379280824 creator A5054101072 @default.
• W4379280824 creator A5061222063 @default.
• W4379280824 creator A5061264992 @default.
• W4379280824 creator A5069659797 @default.
• W4379280824 creator A5074628156 @default.
• W4379280824 creator A5078469824 @default.
• W4379280824 creator A5078562748 @default.
• W4379280824 creator A5091122881 @default.
• W4379280824 date "2023-06-01" @default.
• W4379280824 modified "2023-09-27" @default.
• W4379280824 title "Effect of SARS-CoV-2 mRNA vaccine booster in serologically negative patients with thymic epithelial tumors." @default.
• W4379280824 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e20651" @default.
• W4379280824 hasPublicationYear "2023" @default.
• W4379280824 type Work @default.
• W4379280824 citedByCount "0" @default.
• W4379280824 crossrefType "journal-article" @default.
• W4379280824 hasAuthorship W4379280824A5009712410 @default.
• W4379280824 hasAuthorship W4379280824A5010994601 @default.
• W4379280824 hasAuthorship W4379280824A5015496746 @default.
• W4379280824 hasAuthorship W4379280824A5021770361 @default.
• W4379280824 hasAuthorship W4379280824A5023671070 @default.
• W4379280824 hasAuthorship W4379280824A5024350156 @default.
• W4379280824 hasAuthorship W4379280824A5034331446 @default.
• W4379280824 hasAuthorship W4379280824A5042430456 @default.
• W4379280824 hasAuthorship W4379280824A5046176373 @default.
• W4379280824 hasAuthorship W4379280824A5050025219 @default.
• W4379280824 hasAuthorship W4379280824A5051876165 @default.
• W4379280824 hasAuthorship W4379280824A5052916641 @default.
• W4379280824 hasAuthorship W4379280824A5054101072 @default.
• W4379280824 hasAuthorship W4379280824A5061222063 @default.
• W4379280824 hasAuthorship W4379280824A5061264992 @default.
• W4379280824 hasAuthorship W4379280824A5069659797 @default.
• W4379280824 hasAuthorship W4379280824A5074628156 @default.
• W4379280824 hasAuthorship W4379280824A5078469824 @default.
• W4379280824 hasAuthorship W4379280824A5078562748 @default.
• W4379280824 hasAuthorship W4379280824A5091122881 @default.
• W4379280824 hasConcept C12590561 @default.
• W4379280824 hasConcept C126322002 @default.
• W4379280824 hasConcept C159047783 @default.
• W4379280824 hasConcept C159654299 @default.
• W4379280824 hasConcept C203014093 @default.
• W4379280824 hasConcept C22070199 @default.
• W4379280824 hasConcept C2777451964 @default.
• W4379280824 hasConcept C2779159893 @default.
• W4379280824 hasConcept C32611913 @default.
• W4379280824 hasConcept C45189115 @default.
• W4379280824 hasConcept C71924100 @default.
• W4379280824 hasConceptScore W4379280824C12590561 @default.
• W4379280824 hasConceptScore W4379280824C126322002 @default.
• W4379280824 hasConceptScore W4379280824C159047783 @default.
• W4379280824 hasConceptScore W4379280824C159654299 @default.
• W4379280824 hasConceptScore W4379280824C203014093 @default.
• W4379280824 hasConceptScore W4379280824C22070199 @default.
• W4379280824 hasConceptScore W4379280824C2777451964 @default.
• W4379280824 hasConceptScore W4379280824C2779159893 @default.
• W4379280824 hasConceptScore W4379280824C32611913 @default.
• W4379280824 hasConceptScore W4379280824C45189115 @default.
• W4379280824 hasConceptScore W4379280824C71924100 @default.
• W4379280824 hasIssue "16_suppl" @default.
• W4379280824 hasLocation W43792808241 @default.
• W4379280824 hasOpenAccess W4379280824 @default.
• W4379280824 hasPrimaryLocation W43792808241 @default.
• W4379280824 hasRelatedWork W135347149 @default.
• W4379280824 hasRelatedWork W2080273809 @default.
• W4379280824 hasRelatedWork W2114584134 @default.
• W4379280824 hasRelatedWork W2271934434 @default.
• W4379280824 hasRelatedWork W2401372777 @default.
• W4379280824 hasRelatedWork W3128830683 @default.
• W4379280824 hasRelatedWork W3212149038 @default.
• W4379280824 hasRelatedWork W4200488354 @default.
• W4379280824 hasRelatedWork W4210269439 @default.
• W4379280824 hasRelatedWork W4220708552 @default.
• W4379280824 hasVolume "41" @default.
• W4379280824 isParatext "false" @default.
• W4379280824 isRetracted "false" @default.
• W4379280824 workType "article" @default.